Literature DB >> 26108083

Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma: Systematic review and meta-analysis.

Michael R Gionfriddo1, John B Hagan, Christina R Hagan, Gerald W Volcheck, Ana Castaneda-Guarderas, Matthew A Rank.   

Abstract

BACKGROUND: Many patients with asthma are potentially overtreated, which results in unnecessary cost and unnecessary exposure to drugs that may result in adverse events. Step down helps reduce overtreatment, may mitigate these harms, and is advocated by major guidelines. Unfortunately, data that support step down are sparse.
OBJECTIVES: This systematic review aimed to examine the effect of stepping down from scheduled inhaled corticosteroids (ICS) to as-needed ICS in patients with stable asthma.
METHODS: Several electronic databases were systematically searched in April 2014. Articles were screened independently in duplicate. Studies were required to have at least a 12-week follow-up duration and to have compared stepping down from scheduled ICS to as-needed ICS and maintenance of scheduled ICS. Patients were required to have stable asthma as evidenced by at least 4 weeks without asthma exacerbation before intervention.
RESULTS: A total of 3025 abstracts were retrieved initially, 77 of which were retrieved for full-text screening. Of these, only two articles were found to be eligible for inclusion, both were randomized controlled trials. By using random effects meta-analysis, it was determined that, after a follow-up of 6-10 months, the relative risk of exacerbation of stepping down from scheduled to as-needed ICS was 1.32 (95% confidence interval [CI], 0.81-2.16; p = 0.27, I(2) = 0%). Those who did not step down had more symptom-free days (standard mean difference 0.26 [95% CI, 0.02-0.49; p = 0.03; I(2) = 22%]).
CONCLUSION: There is currently insufficient evidence to associate stepping down from scheduled to as-needed ICS with a change in exacerbations, although it may lead to fewer symptom-free days.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26108083      PMCID: PMC5561078          DOI: 10.2500/aap.2015.36.3850

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  18 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program.

Authors:  Matthew A Rank; Megan E Branda; Deborah B McWilliams; Shirley K Johnson; Shefali A Samant; Jenna C Podjasek; Miguel A Park; Gerald W Volcheck
Journal:  Ann Allergy Asthma Immunol       Date:  2013-03-15       Impact factor: 6.347

Review 5.  The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Matthew A Rank; John B Hagan; Miguel A Park; Jenna C Podjasek; Shefali A Samant; Gerald W Volcheck; Patricia J Erwin; Colin P West
Journal:  J Allergy Clin Immunol       Date:  2013-01-12       Impact factor: 10.793

Review 6.  The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials.

Authors:  J B Hagan; S A Samant; G W Volcheck; J T Li; C R Hagan; P J Erwin; M A Rank
Journal:  Allergy       Date:  2014-02-26       Impact factor: 13.146

Review 7.  Inhaled corticosteroids in children with persistent asthma: effects on growth.

Authors:  Linjie Zhang; Sílvio O M Prietsch; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2014-07-17

Review 8.  Long-acting β2-agonist step-off in patients with controlled asthma.

Authors:  Jan L Brozek; Monica Kraft; Jerry A Krishnan; Michelle M Cloutier; Stephen C Lazarus; James T Li; Nancy Santesso; Robert C Strunk; Thomas B Casale
Journal:  Arch Intern Med       Date:  2012-10-08

Review 9.  Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis.

Authors:  Gustavo J Rodrigo; José A Castro-Rodríguez
Journal:  Respir Med       Date:  2013-06-14       Impact factor: 3.415

Review 10.  Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth.

Authors:  Aniela I Pruteanu; Bhupendrasinh F Chauhan; Linjie Zhang; Sílvio O M Prietsch; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2014-07-17
View more
  2 in total

Review 1.  Stepping down the dose of inhaled corticosteroids for adults with asthma.

Authors:  Iain Crossingham; David Jw Evans; Nathan R Halcovitch; Paul A Marsden
Journal:  Cochrane Database Syst Rev       Date:  2017-02-01

2.  Addressing the challenges of severe asthma.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 Jul-Aug       Impact factor: 2.587

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.